REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Lean Body Recomp

Fat Lossbeginner
44
Share
Peptides

2

Avg Daily mcg

500

Level

beginner

Added

May 16, 2026

Overview

The Lean Body Recomp is a streamlined, beginner-friendly peptide stack engineered for efficient fat loss while preserving lean muscle tissue. By combining AOD-9604, a modified fragment of human growth hormone specifically targeting lipolysis, with Ipamorelin, a selective growth hormone secretagogue, this protocol attacks body fat through dual metabolic pathways without the side effects associated with full-length GH administration. AOD-9604 at 300mcg daily is derived from the fat-burning region of the growth hormone molecule (amino acids 177-191) and has been shown to stimulate lipolysis and inhibit lipogenesis without affecting blood sugar levels or promoting tissue growth. Unlike full-length HGH, it does not cause insulin resistance, water retention, or joint pain, making it an ideal targeted fat-loss agent. Ipamorelin at 200mcg daily complements this by stimulating clean, physiological GH pulses that enhance metabolic rate, support muscle protein synthesis, and improve sleep quality, all of which contribute to favorable body recomposition. The synergy in this stack is elegant: AOD-9604 directly mobilizes stored fat for oxidation while Ipamorelin maintains the anabolic and metabolic environment needed to prevent muscle catabolism during a caloric deficit. The result is a shift in body composition rather than simple weight loss. For optimal results, administer AOD-9604 in the morning on an empty stomach, at least 30 minutes before eating, to maximize its lipolytic window. Ipamorelin is best taken before bed on an empty stomach (no food for 2 hours prior) to amplify nocturnal GH release. Avoid high-fat meals within an hour of either injection. This stack is suited for beginners looking to reduce body fat percentage while maintaining or slowly building lean mass. It works best when paired with a moderate caloric deficit (300-500 calories below maintenance), regular resistance training, and adequate protein intake. Research on AOD-9604 has demonstrated fat reduction without appetite changes, while Ipamorelin studies confirm selective GH release without cortisol or prolactin elevation. Typical cycles run 8-12 weeks.

Dosing Protocol

300 mcg

per dose

200 mcg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.